Clinical trials: Renal Transplant Recipients
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Transplantation
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
- Trial name
- NCT00531063
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation, Graft Survival
Longitudinal Dynamics of AT1R Antibodies in Kidney Transplant Recipients
This study aims to investigate the dynamics of Angiotensin II Type 1 Receptor Antibodies (AT1R-Ab) before and after kidney transplantation.
- Conditions
- Kidney Transplantation, Graft Survival, Angiotensin II Type 1 Receptor Antibody
- Trial name
- AT1R (NCT07374484)
- Where
- South Korea
- Volunteers
- 241 people
- Sponsor
- Seoul National University Hospital
Kidney Transplant Infection
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
This study was designed to compare 3 immunosuppression regimens: sirolimus and tacrolimus versus everolimus and tacrolimus versus mycophenolate and tacrolimus.
- Trial name
- SEM (NCT03468478)
- Testing
- Sirolimus, Everolimus, Mycophenolic acid
- Where
- Brazil
- Volunteers
- 1,209 people
- Sponsor
- Hospital do Rim e Hipertensão
Kidney Transplantation
Urinary Tract Infections in Kidney Transplant Recipients
The purpose of this study is to better estimate the prevalence of urinary tract infections (UTI) in kidney transplant (KIT) recipients, and especially multidrug resistant (MDR) bacteria.
- Trial name
- URIKIT (NCT03211026)
- Testing
- No intervention
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Poitiers University Hospital
Kidney Failure
Immune Monitoring in Sensitized Patients at Risk of Rejection
The purpose of this study is to test the effect of anti-rejection medications on your immune system
- Trial name
- PRISM (NCT03794817)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of California, San Francisco
Glomerulonephritis, IgAN
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence.
- Trial name
- PIRAT (NCT02523768)
- Testing
- ATG-F, Simulect
- Where
- 15 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
CMV Infection, CMV Viremia
Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st…
- Trial name
- NCT06263218
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Hospital do Rim e Hipertensão
BK Virus Infection, BKV Infection
A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection
The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia).
- Conditions
- BK Virus Infection, BKV Infection, Kidney Transplant
- Trial name
- NCT07503561
- Testing
- AIC263029
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- AiCuris Anti-infective Cures AG
Kidney Transplantation Recipients
MPA Pharmacokinetics in Renal Transplantation
Adequate exposure to mycophenolic acid (MPA) is associated with better outcomes in kidney transplantation. This study evaluated repeated, MPA pharmacokinetics (MPA-PK) according to post-transplant time-points and concomitant…
- Trial name
- NCT01892761
- Testing
- Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups
- Where
- Brazil
- Volunteers
- 52 people
- Sponsor
- University of Sao Paulo General Hospital
Kidney Transplant Recipients
Validation of Gene Expression Markers of Renal Allograft Functional Decline
The purpose of this study is to determine if certain genes found in a kidney biopsy performed at one-year post transplant can predict which transplanted kidneys will have decreased kidney function within five years…
- Trial name
- NCT01782586
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Delayed Graft Function
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
The purpose of this pilot study is to evaluate concentration-controlled everolimus with low dose tacrolimus compared to early conversion to CNI-free regimen and MMF/MPA with standard dose tacrolimus in de novo renal transplant…
- Trial name
- Evered (NCT01878786)
- Testing
- Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Matthew Cooper
Delayed Graft Function
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function.
- Trial name
- VARVARA (NCT05907096)
- Testing
- ARGX-117
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- argenx
Hyperparathyroidism
A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients
The purpose of this study is to see if Hyperparathyroidism (HPT) is common in people who receive a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the…
- Trial name
- NCT01163669
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Occurrence of Renal Dysfunction (GFR ≤ 60mL/(Min·1.73m2)) in Renal Transplant Recipients Within One Year After Kidney Transplantation
Multimodal Ultrasound in DBD Kidneys for Predicting Early Postoperative Renal Insufficiency Risk
The objective of this observational study is to investigate the multimodal ultrasound parameters of kidneys from brain-dead organ donors prior to donation, in order to construct a predictive model for assessing the risk of early…
- Trial name
- NCT07090512
- Testing
- Multimodal Ultrasound
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bei Wang
Renal Transplant Failure, Cardiovascular Complication
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.
- Trial name
- CELART (NCT05243446)
- Testing
- Losartan
- Where
- Poland
- Volunteers
- 740 people
- Sponsor
- Medical University of Gdansk
Kidney Transplant
Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients
Outcomes after kidney transplantation have been significantly enhanced with the advances made in immunosuppressive therapies. Tacrolimus is currently marketed as an extended-release once-daily formulation dosing option for…
- Trial name
- NCT03713645
- Testing
- Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Temple University
Kidney Transplant Recipients
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
Acumulating data suggest that thrapeutic drug therapeutic may optimize efficacity and tolerance of MMF. It could guarantee better exposure to the drug in the first 3 months and then minimize side effects in the long term.
- Trial name
- NCT00199667
- Testing
- Mycophenolate Mofetil
- Where
- 11 sites in France
- Volunteers
- 137 people
- Sponsor
- University Hospital, Limoges
Organ Transplantation
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney.
- Trial name
- NCT00565773
- Testing
- Belatacept, Sirolimus, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allan D Kirk, MD, PhD
Hiv, Kidney Transplant
Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
The purpose of this proof of concept, pilot study is to determine whether the unique combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and the mammalian target of rapamycin (mTOR) inhibitor…
- Conditions
- Hiv, Kidney Transplant, HIV Reservoir, CCR5
- Trial name
- NCT02990312
- Testing
- Sirolimus + Maraviroc
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.